Uses of Clofarabine

Clofarabine is an anti-cancer drug, which works to hinder the growth of cancer cells and eventually they will be destroyed by the body. Since normal cell growth may also be affected by Clofarabine, other undesirable effects may occur. Before you start treatment, talk to your doctor about the benefits of this medicine as well as the possible risks of taking it. Clofarabine is indicated in the treatment of acute lymphoblastic leukemia that has relapsed or is refractory to at least two prior regimens and no other treatment option is expected to result in a long-term response. long. The drug is indicated for the treatment of pediatric patients 1 to 21 years of age.

2.1. For adults 18 to under 22 years of age: Dose of 52 mg/m2 (IV infusion over 1-2 hours) daily for 5 consecutive days of a 28-day cycle, repeated every 2 to 6 weeks. Safety and efficacy have not been established in adults >21 years of age. 2.2. For children Children 1 year of age and adolescents:
The recommended dose in monotherapy is 52 mg/m2 body surface area, by intravenous infusion over 2 hours daily for 5 consecutive days of the cycle. 28 days, repeat every 2 to 6 weeks. Body surface area should be calculated using the patient's actual height and weight prior to the start of each cycle.
Treatment cycles should be repeated every 2 to 6 weeks (from the start of the previous cycle) after restoration of normal hematopoiesis (ie absolute neutrophil count ≥ 0) ,75 × 109/L) and return to original organ function. A 25% dose reduction may be warranted in patients experiencing significant toxicity.
The majority of patients who respond to Clofarabine achieve a response after only 1 or 2 cycles of treatment. Therefore, the potential benefits and risks associated with continued treatment in patients with no hematological and/or clinical improvement after 2 cycles of treatment should also be evaluated by the treating physician. .
Children weighing < 20 kg:
Consider infusion time greater than 2 hours to help reduce symptoms of anxiety and irritability, and to avoid excessively high maximum concentrations of Clofarabine.
Children < 1 year:
There are no data on the pharmacokinetics and safety or efficacy of clofarabine in neonates. Therefore, safe and effective dosing recommendations for patients under 1 year of age have not been established.

The most common side effects of Clofarabine include:
Fever, chills, flu symptoms or other signs of infection; Stomach pain, nausea, vomiting, loss of appetite, diarrhea; Fast heart beat ; Nosebleeds, bruising; Pain in your arm or leg; headache, feeling tired or anxious; mild itching or skin rash; or Flushing (warmth, red, or teasing feeling). This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

Some Clofarabine drug interactions include:
Measles virus vaccine Mumps virus vaccine Rotavirus vaccine Rubella vaccine Varicella virus vaccine Zoster vaccine Use this medicine with any medicine The following are generally not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change how much or how often you use one or both medicines.
Adenovirus Bacillus of Calmette and Guerin Vaccine, Live Cholera Vaccine Dengue Chemotherapy Vaccine Influenza Virus Vaccine Poliovirus Vaccine Chickenpox Vaccine Typhoid Vaccine Yellow Fever Vaccine Some The drug should not be used at or around the time of eating food or eating certain foods because interactions can occur. Using alcohol or tobacco with certain medications can also cause interactions. Discuss with your health care professional about taking your medicine with food, alcohol, or tobacco.

The following parameters should be closely monitored for patients being treated with Clofarabine: Complete blood count and platelet count should be done at regular intervals and more frequently in patients with cytopenias. . Renal and liver function before, during and after therapy are actively treated. Clofarabine should be discontinued immediately if significant increases in creatinine, liver enzymes and/or bilirubin are observed. Respiratory status, blood pressure, fluid balance and weight during and immediately after using Clofarabine for 5 days. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal cases, have been reported. Clofarabine should be discontinued in case of exfoliative or bullous rash, or if SJS or TEN is suspected. Clofarabine can lead to serious birth defects when taken during pregnancy. Therefore, you should not use clofarabine for infusion during pregnancy, especially during the first trimester, unless absolutely necessary (when the benefit to the mother will outweigh the risk to the fetus). The drug can be used for subjects who often drive and operate machinery